首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1164086篇
  免费   79779篇
  国内免费   2251篇
耳鼻咽喉   15677篇
儿科学   34725篇
妇产科学   30378篇
基础医学   159540篇
口腔科学   29245篇
临床医学   99219篇
内科学   221007篇
皮肤病学   19505篇
神经病学   98132篇
特种医学   48415篇
外国民族医学   175篇
外科学   184737篇
综合类   29103篇
现状与发展   3篇
一般理论   423篇
预防医学   95518篇
眼科学   25807篇
药学   83010篇
  2篇
中国医学   2369篇
肿瘤学   69126篇
  2018年   32399篇
  2017年   25826篇
  2016年   29730篇
  2015年   10844篇
  2014年   14981篇
  2013年   22287篇
  2012年   36397篇
  2011年   52811篇
  2010年   36994篇
  2009年   29206篇
  2008年   50823篇
  2007年   56810篇
  2006年   32340篇
  2005年   34576篇
  2004年   35276篇
  2003年   35977篇
  2002年   32370篇
  2001年   37318篇
  2000年   38057篇
  1999年   32266篇
  1998年   11007篇
  1997年   10164篇
  1996年   9669篇
  1995年   9204篇
  1994年   8754篇
  1992年   27460篇
  1991年   26889篇
  1990年   26402篇
  1989年   25370篇
  1988年   23837篇
  1987年   23488篇
  1986年   22330篇
  1985年   21795篇
  1984年   17191篇
  1983年   14810篇
  1982年   9953篇
  1981年   9133篇
  1980年   8642篇
  1979年   17248篇
  1978年   12691篇
  1977年   10694篇
  1976年   9785篇
  1975年   10521篇
  1974年   13000篇
  1973年   12420篇
  1972年   11739篇
  1971年   10805篇
  1970年   10382篇
  1969年   10063篇
  1968年   9004篇
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
11.
Gestational trophoblastic neoplasia (GTN) patients are treated according to the eight-variable International Federation of Gynaecology and Obstetrics (FIGO) scoring system, that aims to predict first-line single-agent chemotherapy resistance. FIGO is imperfect with one-third of low-risk patients developing disease resistance to first-line single-agent chemotherapy. We aimed to generate simplified models that improve upon FIGO. Logistic regression (LR) and multilayer perceptron (MLP) modelling (n = 4191) generated six models (M1-6). M1, all eight FIGO variables (scored data); M2, all eight FIGO variables (scored and raw data); M3, nonimaging variables (scored data); M4, nonimaging variables (scored and raw data); M5, imaging variables (scored data); and M6, pretreatment hCG (raw data) + imaging variables (scored data). Performance was compared to FIGO using true and false positive rates, positive and negative predictive values, diagnostic odds ratio, receiver operating characteristic (ROC) curves, Bland-Altman calibration plots, decision curve analysis and contingency tables. M1-6 were calibrated and outperformed FIGO on true positive rate and positive predictive value. Using LR and MLP, M1, M2 and M4 generated small improvements to the ROC curve and decision curve analysis. M3, M5 and M6 matched FIGO or performed less well. Compared to FIGO, most (excluding LR M4 and MLP M5) had significant discordance in patient classification (McNemar's test P < .05); 55-112 undertreated, 46-206 overtreated. Statistical modelling yielded only small gains over FIGO performance, arising through recategorisation of treatment-resistant patients, with a significant proportion of under/overtreatment as the available data have been used a priori to allocate primary chemotherapy. Streamlining FIGO should now be the focus.  相似文献   
12.
Cutaneous leiomyomas are rare benign smooth‐muscle tumors. These lesions are distinguished based on their cell of origin and are subclassified as pilar leiomyoma, angioleiomyoma, and genital‐type leiomyoma. Nipple leiomyoma is the least common genital‐type leiomyoma, arising from the dartoic muscle cell of the nipple. Histologic examination of the lesion is necessary for definitive diagnosis, and these uncommon tumors can pose a diagnostic challenge. We describe herein a series of six nipple leiomyomas with a spectrum of histologic appearances.  相似文献   
13.
14.
15.
16.

Objective

Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.

Methods

Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.

Results

In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.

Conclusions

Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection.  相似文献   
17.
18.
19.
20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号